Viking Therapeutics Inc (VKTX) Receives $28.17 Average Target Price from Analysts

Viking Therapeutics Inc (NASDAQ:VKTX) has received an average recommendation of “Buy” from the nine research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $28.17.

A number of equities research analysts recently weighed in on the company. Raymond James set a $43.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, September 19th. SunTrust Banks lifted their target price on Viking Therapeutics to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, September 19th. Roth Capital lifted their price objective on Viking Therapeutics from $13.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, September 19th. Maxim Group reaffirmed a “buy” rating and set a $28.00 price objective (up from $14.00) on shares of Viking Therapeutics in a report on Tuesday, September 18th. Finally, HC Wainwright set a $28.00 price objective on Viking Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 18th.

In other Viking Therapeutics news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of Viking Therapeutics stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $19.15, for a total transaction of $5,034,171.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.90% of the stock is currently owned by insiders.



Several large investors have recently bought and sold shares of the company. Boxer Capital LLC raised its stake in shares of Viking Therapeutics by 17.7% in the second quarter. Boxer Capital LLC now owns 3,750,000 shares of the biotechnology company’s stock valued at $35,588,000 after acquiring an additional 564,000 shares during the last quarter. BlackRock Inc. raised its position in Viking Therapeutics by 681.0% in the 2nd quarter. BlackRock Inc. now owns 2,938,645 shares of the biotechnology company’s stock worth $27,888,000 after purchasing an additional 2,562,356 shares during the last quarter. Janus Henderson Group PLC bought a new position in Viking Therapeutics in the 2nd quarter worth approximately $19,552,000. Millennium Management LLC raised its position in Viking Therapeutics by 99.1% in the 1st quarter. Millennium Management LLC now owns 1,399,370 shares of the biotechnology company’s stock worth $6,115,000 after purchasing an additional 696,398 shares during the last quarter. Finally, Opaleye Management Inc. raised its position in Viking Therapeutics by 9.0% in the 2nd quarter. Opaleye Management Inc. now owns 1,200,000 shares of the biotechnology company’s stock worth $11,388,000 after purchasing an additional 99,200 shares during the last quarter. Institutional investors own 52.65% of the company’s stock.

VKTX stock traded up $0.99 during trading on Tuesday, reaching $14.29. 3,926,333 shares of the stock were exchanged, compared to its average volume of 3,703,867. Viking Therapeutics has a twelve month low of $2.08 and a twelve month high of $24.00. The company has a market cap of $866.80 million, a PE ratio of -18.09 and a beta of 2.82.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Research analysts predict that Viking Therapeutics will post -0.44 EPS for the current fiscal year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Recommended Story: Google Finance

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply